Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab
ConclusionsOur data continue to support an increased risk of infections with Gram-positive cocci as a potentially serious adverse event in women treated with pertuzumab and trastuzumab.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cellulitis | Chemotherapy | Coccidioidomycosis (Valley Fever) | Docetaxel | Drugs & Pharmacology | HER2 | Herceptin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Taxotere | Women